4148 — All Cosmos Bio-Tech Holding Balance Sheet
0.000.00%
- TWD3.12bn
- TWD2.89bn
- TWD2.46bn
- 78
- 38
- 78
- 75
Annual balance sheet for All Cosmos Bio-Tech Holding, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 851 | 775 | 1,346 | 1,571 | 1,106 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 574 | 458 | 728 | 505 | 663 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,827 | 2,302 | 3,367 | 2,818 | 2,661 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 606 | 629 | 679 | 803 | 939 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 2,614 | 2,970 | 4,111 | 3,674 | 3,671 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 221 | 562 | 682 | 790 | 479 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 628 | 980 | 1,744 | 1,419 | 1,155 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 1,987 | 1,990 | 2,367 | 2,254 | 2,515 |
Total Liabilities & Shareholders' Equity | 2,614 | 2,970 | 4,111 | 3,674 | 3,671 |
Total Common Shares Outstanding |